罗湖城景。 企业带来了超过百项前沿产品。 1月29日，2026"深港同心·罗湖创景"场景创新大会在深圳罗湖云启国际科技金融中心举行，罗湖以"先 锋罗湖，场景沃土"为引领，进一步发挥罗湖在深港合作中的"桥头堡"作用，推动两地场景资源互通、 协同创新，集中力量资源打造"场景城区"。大会吸引了近200位来自深港两地的政府部门代表、创新企 业负责人参与，共商场景创新路径，共谋产业合作未来。 超百项创新成果集中亮相 十大示范性标杆场景揭晓 清单涵盖人工智能等六大领域 首批12个场景合伙人签约 大会当天，一份涵盖41个项目、预计撬动投资超亿元的"创新机会清单"面向全球发布。2026罗湖区首 批"创新机会清单"聚焦开源鸿蒙/RISC-V、空天技术、人工智能等六大前沿领域，本质上是一份"需求说 明书"——清晰告知创新企业:罗湖需要什么、愿意为什么样的解决方案买单。 该清单是罗湖区围绕区域特色与前沿赛道锚定的新目标，涵盖了开源鸿蒙/RISC-V、空天、人工智能、 生命健康、安全节能环保、智慧生活六大核心领域，这些场景不仅是罗湖产业升级与民生改善的突破 口，更是罗湖为全球创新企业搭建的"应用试验场"和"成果转化台"。 本次大会还 ...

1月29日，2026"深港同心·罗湖创景"场景创新大会在深圳罗湖云启国际科技金融中心举行，罗湖以"先 锋罗湖，场景沃土"为引领，进一步发挥罗湖在深港合作中的"桥头堡"作用，推动两地场景资源互通、 协同创新，集中力量资源打造"场景城区"。大会吸引了近200位来自深港两地的政府部门代表、创新企 业负责人参与，共商场景创新路径，共谋产业合作未来。 过百项创新成果集中亮相 十大示范性标杆场景揭晓 在大会展区，41家企业带来的超过百项前沿产品，构成了一幅未来城市生活的微缩图景。这些展品跨越 人工智能、鸿蒙、空天、生命健康、应急安全、智慧治理、智慧生活等多个领域。展区以沉浸式体验与 面对面洽谈相结合的方式，为深港两地企业搭建起高效务实的对接平台，现场促成了多项合作意向。 尤为引人注目的是2025罗湖区十大示范性标杆场景的揭晓，展现罗湖在场景建设方面的阶段性成果与示 范效应。这些场景涵盖多元领域：无人巴士、低空观光、美食节塑造了文旅消费新场景；智慧颐养系统 让居家养老高效便捷；"数智应急"场景筑牢了城市安全防线；教学评一体化智能体赋能家校教育；微软 出海中心助力企业扬帆海外；鸿蒙 ESG 系统守护生态与居住健康；越障机器人 ...

Core Insights - The innovative drug sector is entering a critical performance realization phase in 2026, driven by multiple catalysts and advancements in brain-computer interfaces and AI medical technologies [1][6][7] - Fund managers, including Ouyang Juan from Jinying Fund, express optimism about the innovative drug sector's upward trend, supported by domestic healthcare policies and China's competitive edge in global markets [1][6][7] - The potential of AI in healthcare is significantly underestimated, with expectations for new business models to emerge as AI applications in drug development, cancer screening, and personalized treatment evolve [2][7] Group 1: Industry Outlook - The innovative drug sector is expected to maintain a positive outlook, benefiting from ongoing support from domestic healthcare policies and the global competitiveness of Chinese innovative drugs [1][6] - The year 2026 is anticipated to be pivotal for the brain-computer interface industry, with significant changes expected in both domestic and international markets [3][8] - The AI healthcare sector is entering a phase of commercial exploration, with vast amounts of medical data and a growing demand for AI applications [2][8] Group 2: Investment Strategies - Focus areas for investment include innovative drugs with strong global competitiveness, which can benefit from both domestic and Western markets [3][8] - The innovative drug supply chain, including CXO and life sciences services, is projected to see a recovery in order growth as global financing accelerates [3][8] - The brain-computer interface and AI medical sectors are highlighted as emerging areas of interest, with potential for substantial growth and innovation [2][3][8]

Core Insights - The report maintains a strong market rating for the medical device industry, emphasizing the importance of capitalizing on overseas expansion and the commercialization of AI in healthcare [1][3][5] Medical Device Strategy - The strategy focuses on a three-step approach: prioritizing overseas expansion, benefiting from centralized procurement, and being sensitive to fiscal policies [3][5] - The report highlights the acceleration of overseas growth, particularly in high-value orthopedic, electrophysiology, and robotic sectors, which are expected to be the main contributors to growth in 2025 [5][24] - Companies such as MicroPort, Tianzhihang, and Weigao are recommended for their potential in overseas markets and innovative product offerings [5][24] AI Applications and Brain-Computer Interfaces - The report identifies a significant opportunity in AI applications, with a focus on the commercialization phase driven by policy support and market demand [4][9] - The brain-computer interface sector is poised for growth, with several leading companies expected to go public soon, which could catalyze the market [9][24] Financial Performance and Market Trends - The medical device sector is showing signs of recovery, with Q3 2025 revenues reaching 593.7 billion yuan, a year-on-year increase of 2.9%, indicating a clear upward trend [13][31] - The report notes a significant contraction in fund allocation to the medical device sector, dropping from 24.5% to 15% from Q3 2022 to Q3 2025, suggesting potential for valuation recovery [14][21] Overseas Growth Potential - The report emphasizes the importance of overseas markets, particularly in Europe and the U.S., where companies are transitioning from product-focused strategies to comprehensive commercialization partnerships [5][24] - Key growth areas include surgical robots and high-value consumables, with companies like Tianzhihang and MicroPort leading the charge in international markets [24][30] Fiscal Policy Impact - The report discusses the sensitivity of equipment demand to fiscal policies, with expectations of a more favorable environment as inventory levels decrease and demand normalizes [31][34] - The anticipated release of more proactive fiscal signals in the upcoming years is expected to support the recovery of the medical device sector [31][34]

Group 1 - The core point of the article is that Shengxiang Bio plans to establish a new investment fund with a target size of 1 billion RMB, focusing on AI medical applications and innovative medical technologies [1] - Shengxiang Bio's stock closed at 21.75 RMB, with a market capitalization of 12.602 billion RMB, reflecting a slight increase of 0.09% from the previous trading day [1] - The company will contribute 370 million RMB to the fund, representing a 37% stake, which aims to enhance its strategic layout in the medical field [1] Group 2 - The fund will primarily invest in companies with leading technologies and significant market potential in the medical industry [1] - The investment decision has been approved by the board of directors and will not be included in the company's consolidated financial statements [1] - The funding will be sourced from the company's own or self-raised capital, ensuring no significant adverse impact on its operations [1]